Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Adaptimmune Therapeutics  / Equity Bottom-Up

<ul><li>Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a biopharmaceutical company focused on designing, developing, and delivering innovative cell therapies.</li><li>The company's unique T-cell receptor (TCR) platform engineers T-cells to target and destroy cancers across multiple solid tumor types.</li><li> The company was founded in 2008 and is headquartered in Abingdon, United Kingdom, and Philadelphia, PA.</li></ul>

Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a biopharmaceutical company focused on designing, developing, and delivering innovative cell therapies.The company's unique T-cell receptor (TCR) platform engineers T-cells to target and destroy cancers across multiple solid tumor types. The company was founded in 2008 and is headquartered in Abingdon, United Kingdom, and Philadelphia, PA.

ADAP: Initiating Coverage of Leading T-Cell Therapy Company